Probiotics can protect the skeletons of older women

For the first time in the world, researchers at the University of Gothenburg, Sweden, have demonstrated that probiotics, dietary supplements with health-promoting bacteria, can be used to affect the human skeleton. Among older women who received probiotics, bone loss was halved compared to women who received only a placebo. The research opens the door to a new way to prevent fractures among the elderly.

Brittleness of the bones, or osteoporosis, is characterized by porous and weak bones, which can cause them to break even when subjected to low loads, such as a fall from standing height. The proportion of the population with osteoporosis increases with age, and a majority of women over 80 years of age have the disease.

"Today there are effective medications administered to treat osteoporosis, but because bone fragility is rarely detected before the first fracture, there is a pressing need for preventive treatments," says Mattias Lorentzon, who is a chief physician and professor of geriatrics at Sahlgrenska Academy, University of Gothenburg.

This is the first time that researchers have shown that it is possible to cut age-related bone loss in elderly women in half if they receive health-promoting bacteria, known as probiotics.

Double-blind, randomized study

The study was conducted at Sahlgrenska University Hospital in Mölndal, Sweden, and its results of the study are now being published by the Journal of Internal Medicine. Ninety elderly women, 76 years old on average, ingested a powder that contained either health-promoting bacteria or a placebo every day for a whole year. A random method determined which women received the active treatment with the Lactobacillus reuteri 6475 bacteria and which received powder without bacteria. Neither the researchers nor the women knew who received the active powder during the study.

"When we finished the study after a year, we measured the women's bone loss in their lower legs with a CT scan and compared it with the measurements we made when the study began. The women who received the powder with active bacteria had lost only half as much bone in the skeleton compared with those who received inactive powders," says Anna Nilsson, a chief physician and associate professor at Sahlgrenska Academy, University of Gothenburg. "Another positive outcome from the study was that the treatment was well tolerated and did not produce more side effects than those experienced by women who received the placebo."

A paradigm shift

Research has shown that intestinal bacteria affect the skeleton in mice, but this is the first study in which probiotics were used to reduce bone loss in older people. The discovery could have important implications in the future: "Older women are the group in society most at risk of osteoporosis and fractures. The fact that we have been able to show that treatment with probiotics can affect bone loss represents a paradigm shift. Treatment with probiotics can be an effective and safe way to prevent the onset of osteoporosis in many older people in the future," says Mattias Lorentzon.

Lactobacillus reuteri 6475 is a bacterium believed to have multiple health-promoting properties, and similar bacteria are already used in a variety of supplements on the market. The bacterium is naturally found in the human gastrointestinal tract. Bacteria in the stomach and intestine have received considerable attention in recent years because there is evidence that the composition of our bacterial flora is associated with diseases such as diabetes and obesity. The mechanisms, that is, the ways that the bacteria produce different effects in the body, are not yet clearly understood.

Anna G Nilsson, Daniel Sundh, Fredrik Bäckhed, Mattias Lorentzon.
Lactobacillus reuteri reduces bone loss in older women with low bone mineral density - a randomized, placebo‐controlled, double‐blind, clinical trial.
Journal of Internal Medicine. doi: 10.1111/joim.12805.

Most Popular Now

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...

Pfizer to provide U.S. government with 10 million …

Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candid...